Correction to: Hypertension Research
In the original publication of the article, refs. [11,12,13] were incorrectly published. The corrected lists are provided below:
The original article has been corrected.
References
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al; PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539–48.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Götzinger, F., Kunz, M., Lauder, L. et al. Correction: Arterial hypertension - clinical trials update 2022. Hypertens Res 45, 1528 (2022). https://doi.org/10.1038/s41440-022-00975-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-022-00975-4
